Work

Ibrutinib Monotherapy Produces Long‐term Disease Control in Previously Treated Waldenstrom's Macroglobulinemia. Final Report of the Pivotal Trial (nct01614821).

Year: 2019

Type: article

Abstract: Adverse events (Grade >2) in >5% of patients during active follow-up were: neutropenia (22%); thrombocytopenia (14%), pneumonia (9%); GERD (8%); hypertension (8%); anemia (6%); and skin infection (5%). Seven patients (11%) had an atrial arrhythmia at a median of 4 (range 0-33 months), and 6 continued ibrutinib following medical management of arrhythmia. The findings confirm that ibrutinib is highly active, and produces long-term responses in previously treated WM. Prolonged ibrutinib therapy is associated with deeper responses, including VGPR. Response activity, time to major response, and PFS are impacted by MYD88 and CXCR4 mutation status. Keywords: ibrutinib; Waldenström's macroglobulinemia (WM). Disclosures: Treon, S: Consultant Advisory Role: Pharmacyclics, Janssen; Research Funding: Pharmacyclics.

Source: Hematological Oncology

DOI: 10.1002/hon.141_2629

Authors: S.P. Treon, K. Meid, J. Gustine, G. Yang, L. Xu, C.J. Patterson, I. Ghobrial, J.P. Laubach, Z.R. Hunter, T. Dubeau, L. Palomba, R. Advani, J.J. Castillo

Institutions: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Stanford Medicine

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2953303695

FWCI: 1.74

Cites:

Cited by: 16

Related to: 10